Last reviewed · How we verify

Weifuchun

Yongquan Shi · FDA-approved active Small molecule ✓ Verified May 2026 Quality 0/100

Weifuchun is a Small molecule drug developed by Yongquan Shi. It is currently FDA-approved. Also known as: vitamin.

Weifuchun is being studied as a treatment for Chronic Atrophic Gastritis, Gastric Intestinal Metaplasia, and Gastric Cancer, as well as Chronic Atrophic Gastritis With Hyperplasia. Weifuchun has been used in combination with other interventions, including mononuclear cells and hydrotalcite/L-glutamine and sodium gualenate granules, in clinical trials.

At a glance

Generic nameWeifuchun
Also known asvitamin
SponsorYongquan Shi
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Weifuchun

What is Weifuchun?

Weifuchun is a Small molecule drug developed by Yongquan Shi.

Who makes Weifuchun?

Weifuchun is developed and marketed by Yongquan Shi (see full Yongquan Shi pipeline at /company/yongquan-shi).

Is Weifuchun also known as anything else?

Weifuchun is also known as vitamin.

What development phase is Weifuchun in?

Weifuchun is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing